MeiraGTx Holdings, which is developing gene therapies for disorders of the eye and salivary gland, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. At pricing, the company will command a fully diluted market value of...read more
It's a slow start to the typically-active month of June, but that should change soon. Two companies are targeting a combined $158 million in the week ahead. Deals include Taiwan-based live streaming company M17 Entertainment and gene therapy biotech MeiraGTx.
...read more
MeiraGTx Holdings, which is developing gene therapies for disorders of the eye and salivary gland, announced terms for its IPO on Tuesday. The New York, NY-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to...read more
US IPO Weekly Recap: June kicks off to a slow start with 2 IPO pricings but only one trading
Two IPOs priced in the first week of June; only one has started trading Four companies added to the calendar (including two SPACs) ...read more
Gene therapy biotech MeiraGTx prices IPO at $15 midpoint
MeiraGTx Holdings, which is developing gene therapies for disorders of the eye and salivary gland, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. At pricing, the company will command a fully diluted market value of...read more
US IPO Week Ahead: 2 IPOs in the first week of June; more launches expected
It's a slow start to the typically-active month of June, but that should change soon. Two companies are targeting a combined $158 million in the week ahead. Deals include Taiwan-based live streaming company M17 Entertainment and gene therapy biotech MeiraGTx. ...read more
Gene therapy biotech MeiraGTx sets terms for $75 million IPO
MeiraGTx Holdings, which is developing gene therapies for disorders of the eye and salivary gland, announced terms for its IPO on Tuesday. The New York, NY-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to...read more